Anebulo Pharmaceuticals, Inc.
ANEB
$1.14
$0.065.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 24.63% | 25.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.30% | 79.95% | |||
| Operating Income | -7.30% | -79.95% | |||
| Income Before Tax | -11.92% | -63.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.92% | -63.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.92% | -63.01% | |||
| EBIT | -7.30% | -79.95% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -5.77% | -62.96% | |||
| Normalized Basic EPS | -6.04% | -63.08% | |||
| EPS Diluted | -5.77% | -62.96% | |||
| Normalized Diluted EPS | -6.04% | -63.08% | |||
| Average Basic Shares Outstanding | 5.72% | 0.00% | |||
| Average Diluted Shares Outstanding | 5.72% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||